BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 17616527)

  • 1. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice.
    McConlogue L; Buttini M; Anderson JP; Brigham EF; Chen KS; Freedman SB; Games D; Johnson-Wood K; Lee M; Zeller M; Liu W; Motter R; Sinha S
    J Biol Chem; 2007 Sep; 282(36):26326-34. PubMed ID: 17616527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer's disease.
    Sadleir KR; Kandalepas PC; Buggia-Prévot V; Nicholson DA; Thinakaran G; Vassar R
    Acta Neuropathol; 2016 Aug; 132(2):235-256. PubMed ID: 26993139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
    Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
    Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of Synaptic Amyloid-β Generation through BACE1 Retrograde Transport in a Mouse Model of Alzheimer's Disease.
    Ye X; Feng T; Tammineni P; Chang Q; Jeong YY; Margolis DJ; Cai H; Kusnecov A; Cai Q
    J Neurosci; 2017 Mar; 37(10):2639-2655. PubMed ID: 28159908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes.
    Ly PT; Wu Y; Zou H; Wang R; Zhou W; Kinoshita A; Zhang M; Yang Y; Cai F; Woodgett J; Song W
    J Clin Invest; 2013 Jan; 123(1):224-35. PubMed ID: 23202730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of BACE1 haploinsufficiency on APP processing and Aβ concentrations in male and female 5XFAD Alzheimer mice at different disease stages.
    Devi L; Ohno M
    Neuroscience; 2015 Oct; 307():128-37. PubMed ID: 26314636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's disease.
    Andrew RJ; Fernandez CG; Stanley M; Jiang H; Nguyen P; Rice RC; Buggia-Prévot V; De Rossi P; Vetrivel KS; Lamb R; Argemi A; Allaert ES; Rathbun EM; Krause SV; Wagner SL; Parent AT; Holtzman DM; Thinakaran G
    Proc Natl Acad Sci U S A; 2017 Nov; 114(45):E9665-E9674. PubMed ID: 29078331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis.
    Zhao J; Fu Y; Yasvoina M; Shao P; Hitt B; O'Connor T; Logan S; Maus E; Citron M; Berry R; Binder L; Vassar R
    J Neurosci; 2007 Apr; 27(14):3639-49. PubMed ID: 17409228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease.
    Liang B; Duan BY; Zhou XP; Gong JX; Luo ZG
    J Biol Chem; 2010 Sep; 285(36):27737-44. PubMed ID: 20595388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BACE1 elevation engendered by GGA3 deletion increases β-amyloid pathology in association with APP elevation and decreased CHL1 processing in 5XFAD mice.
    Kim W; Ma L; Lomoio S; Willen R; Lombardo S; Dong J; Haydon PG; Tesco G
    Mol Neurodegener; 2018 Feb; 13(1):6. PubMed ID: 29391027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BACE1 elevation is involved in amyloid plaque development in the triple transgenic model of Alzheimer's disease: differential Aβ antibody labeling of early-onset axon terminal pathology.
    Cai Y; Zhang XM; Macklin LN; Cai H; Luo XG; Oddo S; Laferla FM; Struble RG; Rose GM; Patrylo PR; Yan XX
    Neurotox Res; 2012 Feb; 21(2):160-74. PubMed ID: 21725719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer's disease mutations but not by inhibition of BACE1.
    Johnson ECB; Ho K; Yu GQ; Das M; Sanchez PE; Djukic B; Lopez I; Yu X; Gill M; Zhang W; Paz JT; Palop JJ; Mucke L
    Mol Neurodegener; 2020 Sep; 15(1):53. PubMed ID: 32921309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer's disease transgenic mice.
    Kimura R; Devi L; Ohno M
    J Neurochem; 2010 Apr; 113(1):248-61. PubMed ID: 20089133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
    Natunen T; Takalo M; Kemppainen S; Leskelä S; Marttinen M; Kurkinen KMA; Pursiheimo JP; Sarajärvi T; Viswanathan J; Gabbouj S; Solje E; Tahvanainen E; Pirttimäki T; Kurki M; Paananen J; Rauramaa T; Miettinen P; Mäkinen P; Leinonen V; Soininen H; Airenne K; Tanzi RE; Tanila H; Haapasalo A; Hiltunen M
    Neurobiol Dis; 2016 Jan; 85():187-205. PubMed ID: 26563932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic inhibition of phosphorylation of the translation initiation factor eIF2α does not block Aβ-dependent elevation of BACE1 and APP levels or reduce amyloid pathology in a mouse model of Alzheimer's disease.
    Sadleir KR; Eimer WA; Kaufman RJ; Osten P; Vassar R
    PLoS One; 2014; 9(7):e101643. PubMed ID: 24992504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combination Alzheimer's therapy targeting BACE1 and neprilysin in 5XFAD transgenic mice.
    Devi L; Ohno M
    Mol Brain; 2015 Mar; 8():19. PubMed ID: 25884928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aβ reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level.
    Sadleir KR; Eimer WA; Cole SL; Vassar R
    Mol Neurodegener; 2015 Jan; 10():1. PubMed ID: 25567526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of the expression of the late-onset Alzheimer's disease (AD) risk-factor
    Andrew RJ; De Rossi P; Nguyen P; Kowalski HR; Recupero AJ; Guerbette T; Krause SV; Rice RC; Laury-Kleintop L; Wagner SL; Thinakaran G
    J Biol Chem; 2019 Mar; 294(12):4477-4487. PubMed ID: 30692199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BACE1: the beta-secretase enzyme in Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.